Previous studies have demonstrated the beneficial activity of activated
protein C in allergic diseases including
bronchial asthma and
rhinitis. However, the exact mechanism of action of activated
protein C in
allergies is unclear. In this study, we hypothesized that pharmacological doses of activated
protein C can modulate allergic
inflammation by inhibiting dendritic cells.
MATERIALS AND METHODS: Activated
protein C significantly increased the differentiation of tolerogenic plasmacytoid dendritic cells and the secretion of
type I interferons, but it significantly reduced
lipopolysaccharide-mediated maturation and the secretion of inflammatory
cytokines in myeloid dendritic cells. Activated
protein C also inhibited maturation and the secretion of inflammatory
cytokines in monocyte-derived dendritic cells. Activated
protein C-treated dendritic cells were less effective when differentiating naïve CD4 T-cells from Th1 or Th2 cells, and the cellular effect of activated
protein C was mediated by its receptors. Mice that received adoptive transfer of activated
protein C-treated
ovalbumin-pulsed dendritic cells had significantly less
airway hyperresponsiveness, significantly decreased lung concentrations of Th1 and Th2
cytokines, and less plasma concentration of
immunoglobulin E when compared to control mice.
CONCLUSION: